TitleCOPDmedia is a System for the detection and the early prediction of the approaching of exacerbations in patients suffering from Chronic Obstructive Pulmonary Disease (COPD)
Project id.145
Reference sectorBIOTECHNOLOGY
IP Protection LevelInternational Patent Application: PCT/IT2015/000146 (System for the detection and the early prediction of the approaching of exacerbations in patients suffering from Chronic Obstructive Pulmonary Disease). We are waiting to receive the number of the patent applications filed in theese countries: Brazil, China, Japan, U.S.A., Europe, Russia, India .
Description of the innovation projectCOPD is the fourth leading cause of death in the world with a prevalence estimated at 4.5% (300 millions people in worldwide). COPD is often aggravated by acute episodes called exacerbation, from 2 to 4 flare-ups per year, and this represents the first leading cause of hospitalization and death. COPDmedia is an innovative medical device CE certificated. It consists of a Bluetooth oximeter an APP for Smartphone that allows patients to monitor every day their health state and detect the onset of flare-ups and critical clinical situations and avoid potential dangerous situations before symptoms appear. The device is able to detect potentially critical situations with a 98,4% accuracy index.
State of dev.Product
Industrial applicationHealth sector with application to COPD patients. It can be used in other pulmonary or non-pulmonary pathologies that may involve the respiratory system, including heart failure, severe obesity, neuromuscular diseases with respiratory muscle involvement. It is a device that paves the way for a concrete path of "Proactive Medicine" because it offers answers to the health needs of citizens in their living environments. Patient acquires autonomy in the self-control of his pathology wherever he is
Market segmentWorldwide COPD prevalence is between 4 and 5%: in Europe there are 29 million of COPD patients, 300 million in the world. COPDmedia will be sold by e-Commerce and pharmacies according to a BtoC model. The commercial value of the Kit is 180 Euro and a renewal is 60 Euro per year. The potential value of the market is several billion dollars.
Advantage factorThe early diagnosis of COPD exacerbations is problematic because the patient tends to underestimate the symptoms and then comes to the doctor's attention late. Currently there is no methodology outlined but it has emerged the scientific need to identify parameters that are able to tell the doctor the best time to intervene. COPDmedia detect the onset of exacerbations or clinically critical situations before the symptoms arise for an early intervention
Commercial challengeCOPDmedia will be marketed in January 2018.The commercialization will allow us to enter the market, have a turnover and structure us. Given the size of the market and product innovation, we hope to conquer a significant market share in a short time through the distribution channel of ecommerce and pharmacies. We also expect to hire various professional figures.
Publications and Customer ReferecesCOPDmedia is the result of a study carried out in cooperation with Campus Biomedico University (Rome). Patent Application PCT/IT2015/000146. IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI), Las Vegas 2016 [“On the Remote Detection of COPD-Related Worrisome Events”–BHI 2016]. IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS, VOL. 21, NO. 2, MARCH 2017 [A Decision Support System for Tele-Monitoring COPD-Related Worrisome Events]. Front Cover of the same Journal

Proposal of cooperation agreementCommercial representative, Venture capital financing, Distribution Agreement, Sub-contracting Agreement, Buyers